Alvin F Wells (Alvin Wells)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Rheumatoid Arthritis

Drug Administration

Disease Activity

Top Venues

Advances in therapy

Rheumatology and therapy

The Journal of rheumatology

Clinical rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy 41 (5) (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy 41 (5) (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy 41 (5) (2024)
Alan J Kivitz, Alvin F Wells, Juan de J Vargas, Herbert S B Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and therapy (2023)
Alan J Kivitz, Alvin F Wells, Juan de J Vargas, Herbert S B Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and therapy (2023)
Alice B Gottlieb, Alvin F Wells, Joseph Frank Merola
Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists. Clinical rheumatology 41 (5) (2022)
Phillip J Mease, Arthur Kavanaugh, Philip S Helliwell, Alvin F Wells, Martin Bergman, Dafna D Gladman, Sven Richter, Lichen Teng, Shauna Jardon, Josef S Smolen
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. The Journal of rheumatology 49 (7) (2022)